Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INCB161734

Small molecule · Inhibitor of KRAS G12D mutant protein (KRAS) · developed by Incyte

Phase 3 Most advanced trial
INCY Developer
1 Registered trials

What is INCB161734?

INCB161734 is an orally bioavailable inhibitor that specifically binds the oncogenic KRAS G12D mutant protein, preventing its signaling and activation of downstream survival pathways. It is studied in solid tumors, including pancreatic neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
KRAS G12D mutant protein (KRAS)
Mechanism
Inhibitor of KRAS G12D mutant protein (KRAS)
Pathways
KRAS signaling, downstream survival pathways
Therapy area
Oncology
Developer
Incyte Corporation (INCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07522073 Phase 3 Solid Tumors Recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumors

Other drugs acting on KRAS

More from Incyte

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind INCB161734

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.